Search Results - "Sahakian, Eva"
-
1
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Published in Clinical cancer research (15-09-2010)“…Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies…”
Get full text
Journal Article -
2
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Published in Frontiers in immunology (01-08-2022)“…Regulatory T cells (Tregs) are responsible for maintaining immune homeostasis by controlling immune responses. They can be characterized by concomitant…”
Get full text
Journal Article -
3
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Published in International journal of molecular sciences (07-06-2024)“…Although preclinical investigations have shown notable efficacy in solid tumor models utilizing in vitro-differentiated Th17 cells for adoptive cell therapy…”
Get full text
Journal Article -
4
The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells
Published in The Journal of biological chemistry (25-07-2008)“…A defining characteristic of solid tumors is the capacity to divide aggressively and disseminate under conditions of nutrient deprivation, limited oxygen…”
Get full text
Journal Article -
5
Mycovirus-Containing Aspergillus flavus Alters Transcription Factors in Normal and Acute Lymphoblastic Leukemia Cells
Published in International journal of molecular sciences (01-10-2024)“…Transcription factors control genes to maintain normal hemopoiesis, and dysregulation of some factors can lead to acute lymphoblastic leukemia (ALL)…”
Get full text
Journal Article -
6
A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs
Published in The Journal of immunology (1950) (15-09-2014)“…APCs are critical in T cell activation and in the induction of T cell tolerance. Epigenetic modifications of specific genes in the APC play a key role in this…”
Get full text
Journal Article -
7
Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology
Published in Journal of leukocyte biology (01-08-2017)“…Expression of HDAC11 may be involved in myeloid cell biology. Epigenetic changes in chromatin structure have been recently associated with the deregulated…”
Get full text
Journal Article -
8
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model
Published in Frontiers in immunology (23-11-2020)“…Development of chronic lymphocytic leukemia (CLL) is associated with severe immune dysfunction. T-cell exhaustion, immune checkpoint upregulation, and increase…”
Get full text
Journal Article -
9
Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75
Published in Molecular cancer (28-08-2009)“…Hormone-refractory prostate cancer (HRPC) is characterized by poor response to chemotherapy and high mortality, particularly among African American men when…”
Get full text
Journal Article -
10
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia
Published in Blood advances (26-09-2017)“…Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as ibrutinib and idelalisib, are known to show activity in chronic lymphocytic…”
Get full text
Journal Article -
11
IL-7 Dependence in Human B Lymphopoiesis Increases during Progression of Ontogeny from Cord Blood to Bone Marrow
Published in The Journal of immunology (1950) (01-04-2009)“…IL-7 is critical for B cell production in adult mice; however, its role in human B lymphopoiesis is controversial. One challenge was the inability to…”
Get full text
Journal Article -
12
Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells
Published in Molecular cancer therapeutics (01-06-2010)“…Clusterin (CLU), in its cytoplasmic form, is abundant in many advanced cancers and has been established to be cytoprotective against chemotherapeutic agents…”
Get full text
Journal Article -
13
Exposure to a mycovirus containing Aspergillus Flavus reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controls
Published in Cancer treatment and research communications (2021)“…•A mycovirus containing Aspergillus Flavus (MCAF) was cultured from the home of a patient with acute lymphoblastic leukemia (ALL).•Culture was evaluated by…”
Get full text
Journal Article -
14
Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity
Published in Cancer research (Chicago, Ill.) (01-09-2012)“…Mantle cell lymphoma (MCL) is an aggressive and incurable subtype of B-cell non-Hodgkin lymphomas. Although patients often respond initially to first-line…”
Get full text
Journal Article -
15
-
16
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
Published in Blood advances (13-06-2023)“…[Display omitted] T helper 17 (Th17) cells have a prominent role in autoimmune diseases. In contrast, the nature of these cells in cancer is controversial,…”
Get full text
Journal Article -
17
Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eµ-TCL1 Murine Model
Published in Blood (15-11-2022)Get full text
Journal Article -
18
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Published in Scientific reports (16-04-2019)“…Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment…”
Get full text
Journal Article -
19
Efficacy of Combinatorial Treatment Approaches in CTCL
Published in Blood (15-11-2022)Get full text
Journal Article -
20
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
Published in Leukemia research (01-11-2018)“…•Inhibition of pSTAT3 may alter the bone marrow and sensitize CML stem cells to TKI.•Ruxolitinib and nilotinib can be safely combined in patients with…”
Get full text
Journal Article